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ABSTRACT
Introduction: Proteomic techniques offer insights into the molecular perturbations occurring in mus-
cular-dystrophies (MD). Revisiting published datasets can highlight conserved downstream molecular
alterations, which may be worth re-assessing to determine whether their experimental manipulation is
capable of modulating disease severity.
Areas covered: Here, we review the MD literature, highlighting conserved molecular insights warrant-
ing mechanistic investigation for therapeutic potential. We also describe a workflow currently proving
effective for efficient identification of biomarkers & therapeutic targets in other neurodegenerative
conditions, upon which future MD proteomic investigations could be modelled.
Expert commentary: Studying disease models can be useful for identifying biomarkers and model
specific degenerative cascades, but rarely offer translatable mechanistic insights into disease pathology.
Conversely, direct analysis of human samples undergoing degeneration presents challenges derived
from complex chronic degenerative molecular processes. This requires a carefully planed & reproducible
experimental paradigm accounting for patient selection through to grouping by disease severity and
ending with proteomic data filtering and processing.
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1. Introduction
The muscular dystrophies (MDs) are a superfamily of heritable
heterogeneous disorders that exhibit similar clinical and
pathological features in those affected [1–6]. It is estimated
that MDs affect as many as 1 in 6200 people worldwide and
costs exceed $1 billion per year in the United States alone [5].
To date, there are upward of 50 discrete diseases, each of
which is defined by a distinct genetic mutation and can be
inherited as autosomal dominant, autosomal recessive,
X-linked or, in rare cases, may develop sporadically [2,5].
Patients commonly present with progressive weakness in the
appendicular, axial, and maxillofacial muscles but the age of
onset, severity of disease, and concomitant complications vary
dramatically between individuals [1,4–7]. The distribution of
muscle weakness often promotes distinction between the
particular types of disease [1]. As such, MDs have been cate-
gorized into various groups based upon clinical and molecular
observations; these include but are not limited to Duchenne
muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1),
facioscapulohumeral muscular dystrophy (FSHD), limb-girdle
muscular dystrophy (LGMD), Emery–Dreifuss muscular dystro-
phy (EDMD), and collagen VI myopathies.
Recent advances in molecular genetics have promoted
further understanding of the mechanisms governing the var-
ied types of MDs. Studies have identified over 30 causative
genes [1–3] that are involved in the pathogenesis of these
diseases (DMD: 1 gene; FSHD: 2 genes; LGMD: 25 genes;
EDMD: 6 genes; collagen VI: 3 genes); most of which appear
to be protein coding. Localization studies of MD-related can-
didates indicate perturbations may occur in the skeletal mus-
cle sarcolemma, nuclear membrane, extracellular matrix, inter
mediate filament network, and sarcomere [1,3,8]. Despite this,
the functions, pathways, and downstream targets of these
proteins remain to be elucidated. For efficacious therapeutic
targeting of MDs, it is imperative that research focuses on the
downstream networks of each particular mutation to assess
where intervention may restore cellular homeostasis. Prot
eomic technologies are well equipped to examine such pro-
cesses and various laboratories have begun utilizing these
techniques for identification of biomarkers and novel remedial
candidates in MDs.
In this review, we will outline the relative complexities of
studying MDs and how these may be addressed by utilizing
modern proteomic approaches. We aim to discuss the current
knowledge concerning the most common MD – DMD and some
of the less prevalent forms including DM1, FSHD, LGMD, EDMD,
and collagen VI myopathies. Here, we summarize proteomic-
derived advancements in our understanding of these conditions
to date and, where possible and/or appropriate, highlight con-
served downstream molecular perturbations which may prove
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useful as novel biomarkers for disease progression and future
therapeutic investigations.
2. The dystrophies
2.1. DMD
DMD is the most common dystrophy and (to date) the most
thoroughly investigated using proteomic methodologies.
DMD is a recessive X-linked disease, characterized by muscle
degeneration and premature death, typically by the age of
20–30 years. With an incidence of approximately 11–28/
100,000 males, DMD is one of the most common and severe
types of MD [8]. The cause of DMD is a mutation in the
dystrophin gene, leading to an absence of the cytoskeletal
protein, dystrophin [9], and subsequent weakening of the
structural integrity of muscle cells. The majority of therapeutic
approaches for DMD have focused on restoring dystrophin
production by modulation of RNA using antisense oligonu-
cleotides [10]. The development of alternative and/or comple-
mentary therapeutic strategies to target modifiers of DMD
(reviewed by Vo and McNally, 2015 [11]) or the consequence
of downstream pathology [12] appears to be emerging areas
of research. For work in this area to progress, however, a
detailed understanding of the molecules and pathways
involved in DMD is required.
2.2. DM1
DM1 typically manifests in early adulthood and is classified as
a multisystemic neuromuscular disease [5,13] It is the second
most prevalent dystrophy, but most prevalent adult-onset MD
affecting up to 1 in 8000 individuals worldwide [14]. The
disease displays an autosomal dominant mode of inheritance
and patients often present with highly heterogeneous symp-
toms including clinical myotonia, progressive muscular weak-
ness, cardiac arrhythmia, visual disturbances, and insulin
resistance [5,14]. These diverse phenotypes are caused by a
large expansion of the (CTG)n trinucleotide repeat in the 3′
untranslated region of the dystrophia myotonica protein
kinase gene on chromosome 19q13.3 [5,13,15]. Patients with
substantial amplifications of these CTG repeats demonstrate
more severe phenotypes and often present with symptoms at
a much earlier age, promoting a diminished life span [14,15].
Broadly speaking, the clinical diversity of DM1 phenotypes
appears to stem from the sequestration of mutant RNA tran-
scripts encoded by the CTG expansion [13,15]. These tran-
scripts accumulate within the nuclei of various tissues and
promote perturbations in the pathways that regulate altera-
tive splicing programs. Mis-splicing of numerous genes has
been experimentally observed in DM1 patient tissues and
mutant cell lines suggesting that patient phenotypes may be
attributed to the aberrant expression of muscle-specific Cl−
channels, cardiac troponin T, insulin receptors, and the sarco-
plasmic Ca2+ ATPases [13,15–17]. Although alternative splicing
appears to demonstrate some involvement within the devel-
opment and pathogenesis of DM1, there remains a lack in
understanding of how mechanistic pathways could be thera-
peutically targeted to ameliorate disease progression.
2.3. FSHD
FSHD is the third most prevalent of the MDs and is an auto-
somal dominant disease with variable penetrance [18,19].
Typically, as the name suggests, patients present with weak-
ness in the maxillofacial muscles and shoulder girdle, which
subsequently progresses to affect the pelvis and lower extre-
mities [18–20]. The onset, progression, and severity of FSHD
are highly variable between and within families and patients
can range from asymptomatic to critical [19]. Unlike other
MDs, FSHD usually emerges in adulthood with diagnosis typi-
cally occurring in the second or third decade [1,19,20].
However, there are reports of patients presenting with early
FSHD symptoms in their 60s and 70s [18–20], highlighting the
heterogeneity of the disease.
The clinical variability of FSHD likely stems from the muta-
tion the patient is harboring. The most common form of the
disease, FSHD1, is the result of a contraction of microsatellite
repeats in the D4Z4 element located on the 4q35 subtelo-
meric region on chromosome 4 [6,18–21]. Patients typically
present with 1–10 D4Z4 repeats whereas the general popula-
tion demonstrate 11–100 [6,18–21]. Correlations between the
repeat size and clinical severity of patients have been reported
with those harboring 1–3 copies often more severe than
individuals with 8–10 copies [18,19]. Evidence suggests that
this reduction in D4Z4 copies induces chromatin remodeling
promoting cellular toxicity and degeneration in skeletal mus-
cle [20]. Although there are no obvious mutations in any
protein-coding gene, it has been proposed that there may
be erroneous activation of the DUX4, FRG1, FRG2, and ANT1
genes that are located centromeric of the D4Z4 array [18,20].
Little is currently known about the molecular cascades that are
responsible for the clinical manifestation of FSHD due to the
challenging nature of the disease; thus, the identification of
therapeutic targets remains in its infancy. Systematic analyses
utilizing ‘-omics’ data will be invaluable in the field in order to
establish biomarkers of disease and efficacious treatments for
FSHD patients.
2.4. LGMDs
LGMDs are a group of inherited diseases characterized by
progressive weakness and wasting of shoulder and pelvic
girdle muscles. Broadly, there are 2 subcategories of LGMD:
those which display a dominant manner of inheritance,
termed LGMD1 (upward of 8 subtypes), and those which are
recessive in nature, LGMD2 (with approximately 20 subtypes)
[22]. The overall frequency of LGMDs is 20–40/100,000 indivi-
duals [23] with clinical onset typically occurring during the
second decade of life [22] The most extensively studied sub-
types of the disease include LGMD2A, LGMD2B, and LGMD1B
and the molecular genetics underpinning these conditions are
now beginning to be unraveled. Recent studies have sug-
gested that LGMD2A may be caused by mutations in cal-
pain-3 [24] which promotes the loss of autocatalytic function
within skeletal muscle, stimulating fiber degeneration and
atrophy [25]. Although there are indications that calpain-3 is
involved in the pathophysiology of LGMD2A, the function of
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the protein is still to be established, providing complexities in
experimental design and interpretation.
LGMD2B is also believed to be caused by mutations in a
calcium-handling protein [26]. Patients presenting with
LGMD2B demonstrate mutations in the dysferlin (DYSF) gene
[27], which encodes a membrane-associated protein localized
to the sarcolemma. Dysferlin has been noted for its capacity to
aid in membrane regeneration and impairments in its function
appear to stimulate myonecrosis due to increased calcium
influx in skeletal muscle. These pathological processes are
thought to lead to the characteristic shoulder and pelvic girdle
weakness [28] LGMD1B, like subtypes of EDMD, is caused by
mutations in the lamin A/C (LMNA) gene [29,30] Mutations in
this gene result in a diverse range of phenotypes often with
muscular and/or cardiac involvement; however, it is not clear
how LMNA contributes to these clinical manifestations.
Studying the molecular pathways involved downstream of
LGMD mutations is especially challenging due to the hetero-
geneity of genetic mutations, complex clinical diagnosis, and
availability of human samples.
2.5. EDMD
EDMD affects 1 in 100,000 males [31] and is characterized by
scapulohumeroperoneal muscle weakness, joint contractures,
and cardiac defects that include arrhythmias and dilated car-
diomyopathy [32]. Onset of EDMD is typically seen during
childhood or early adolescence [33] and is caused by muta-
tions in various genes that are localized to the nuclear envel-
ope [34]. Commonly, the disease is X-linked recessive and is
associated with mutations in the emerin (EMD) gene, which
consequently causes the truncation of emerin proteins (in
around two-thirds of patients). However, multiple subtypes
mediated by a range of genetic mutations in the autosomes
also exist (for more information, see Pillers & Bergen [35]). As
discussed in Section 2.4, a degree of homology exists between
LGMD1B and autosomal dominant EDMD due to both sub-
types demonstrating mutations in the LMNA gene. Although it
is poorly understood how mutations in lamin A/C contribute
to the LGMD phenotype, EDMD is believed to be caused by
single amino acid substitutions that result in destabilization of
the protein promoting nuclear fragility [36]. Less prevalent
autosomal dominant forms of the disease have demonstrated
loss of function mutations in the nesprin-1 (SYNE1 gene) and
nesprin-2 (SYNE2 gene) proteins (OMIM no. 310300) fostering
perturbations in nuclear architecture [37].
2.6. Collagen VI myopathies
Collagen VI is a ubiquitously expressed extracellular matrix
protein (ECM) composed of threefolded chains that form
dimers and tetramers. In muscle, the collagen VI network sur-
rounds the basement membrane transferring mechanical and
biochemical signals from the ECM to the fiber [38]. Mutations in
any of these genes can cause dysfunction in the microfibrilar
network in the ECM of muscle, skin, and tendons leading to
muscle weakness, joint laxity, contractures, and respiratory
compromise [39]. Dominant and recessive mutations in
collagen VI are often associated with the COL6A1, COL6A2,
and COL6S3 genes and lead to two types of MD: Ullrich con-
gential muscular dystrophy (UCMD) and Bethlem myopathy
(BM) [40–42]. These diseases are relatively rare with an esti-
mated prevalence of 0.1 in 100,000 and 0.5 in 100,000, respec-
tively [43]. UCMD is an autosomal recessive disorder, typically
presenting at birth, with infants demonstrating hypotonia and
congenital hip dislocation. The majority of patients do not
reach the major motor milestones and struggle to walk inde-
pendently. Accompanying the motor symptoms is severe
respiratory problems that require intervention during the first
or second decade of life [44]. BM is phenotypically milder than
UCMD with patients demonstrating a near normal life span
[42,45]. Despite this, it is estimated that 50% of individuals
require ambulatory assistance after the age of 50 due to the
progressive deterioration of muscle and joint integrity [46]. For
a comprehensive review, see Lampe and Bushby [43].
3. Unraveling downstream dystrophic cascades
through proteomic investigations
As highlighted in Sections 2.1–2.6, there are numerous MD
variants aside from the most well-known DMD, caused by a
wide range of associated genetic mutations. There are cur-
rently no treatments that ameliorate the neuromuscular phe-
notype and molecular pathology of any of these diseases [2].
Although several clinical trials for novel therapeutics are in
progress, there remains a lack of understanding of the basic
molecular biology underpinning these diseases. To identify
efficacious pharmacologic targets, it is imperative that the
field utilizes modern ‘-omic’ technologies to examine the path-
ways and processes that are perturbed and how these may
regulate downstream pathology. This will facilitate a broader
understanding of the molecular mechanisms governing mus-
cle development, stability, and pathogenesis and will ulti-
mately enable data-driven interventions that will benefit
patients significantly.
As many as 50 discrete diseases fall under the umbrella of
the dystrophies but at the time of writing this manuscript,
there are only around 26 published proteomic investigations
carried out on dystrophy patient or model systems. Of these,
19 studies are focused on the most prevalent and widely
known DMD (Supplementary Table 1 [15,18,20,21,39,81–83])
whilst the remaining 8 surround the other less pervasive forms
described above (DM1, FSHD, LGMD, EDMD, and collagen VI
myopathies; Supplementary Table 3).
3.1. The search for differentially expressed proteins in
DMD versus control tissues
To date, approximately 19 separate publications from several
different research groups have utilized unbiased quantitative
proteomics technologies to identify differentially expressed
proteins in models of DMD compared to control subjects. All
but one of these studies were conducted in vivo, with dia-
phragm, cardiac, and various skeletal muscles being the most
popular tissue source. Whilst the vast majority of these studies
have utilized the mdx mouse model of DMD, material from
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DMD patients [47,48] as well as the spontaneous golden
retriever muscular dystrophy model [49] have also been inves-
tigated (summarized in Supplementary Table 1 [47–49,54–
56,71–74,91–98]). Though these experiments have generated
a wealth of information, there are several potential issues that
may hamper the translation of findings when the data sets are
considered in isolation. For these reasons, the focus of discus-
sion in the following section will be on proteins that were
consistently changed in expression across three or more of the
separate proteomic comparisons listed in Supplementary
Table 1. This approach also limits the pool of useable studies.
For example, although Ge et al. may have carried out the first
of these proteomic studies in 2003, we are unable to include
their results in our comparative analysis as the data sets are
not freely available [50]. Review of these data sets revealed 34
proteins that met these criteria and are summarized in
Supplementary Table 2 [49–50,54–56,71–74,92–95,97–100].
3.1.1. Increased expression of structural proteins in DMD
The type III intermediate filament proteins, desmin and vimen-
tin, were consistently increased across 8 and 15 comparisons
of DMD tissues, respectively. Considered as a hallmark of
developing myotubes [51], the high expression of both pro-
teins had previously been documented in regenerating muscle
fibers from different neuromuscular diseases, including DMD
[52,53]. Other structural proteins were also consistently
increased in DMD tissue across multiple proteomic compari-
sons, including beta-tubulin, lamin A/C, lamin B1, and spectrin
alpha chain, as well as proteins associated with protein assem-
bly (e.g. elongation protein, protein disulfide-isomerase A3)
(Supplementary Table 2). One possible explanation for this
apparent structural reorganization is that it may represent an
attempted compensatory response to stabilize the weakened
cytoskeleton [54]. It is interesting to note that increased levels
of desmin were also detected in a proteomics study of the
mildly affected (and thus, non-regenerating) extraocular mus-
cle (EOM) from the mdx mouse [55], lending support to this
notion. The possibility, however, that the changes in structural
proteins may merely depict the ongoing process of cellular
degeneration and/or fibrosis must also be considered [56].
3.1.2. Cellular stress responses in DMD
Several proteins associated with a cell stress response were
elevated in multiple proteomic studies of DMD tissue
(Supplementary Table 2), including the heat shock proteins
90, 70, 71, and 78 kDa glucose protein (also known as heat
shock 70 kDa protein 5). Thought to represent a molecular
response to cell stress, the increased expression of heat shock
proteins correlates well with their known involvement in dys-
trophin-deficient muscles [57].
Increased expression of oxidative stress markers including
hemopexin and glutathione-S-transferase (GST) was detected
across several different proteomic studies of DMD (Supple
mentary Table 2). Glutathione metabolism is clearly dysregulated
in dystrophic muscle [58,59], but the cause and functional con-
sequences of this are unclear. While one report has proposed a
model in which altered glutathione metabolism represents an
adaptive and attempted compensatory response to oxidative
stress [58], others argue that the dysregulation of this pathway
may actually be the cause of increased oxidative stress in DMD
[59,60]. Reports of GST activity levels in DMD are also contra-
dictory. While one report demonstrated a marked reduction of
GST activity in muscle from DMD patients [59], a study of the
chicken model of DMD demonstrated a reduction of activity [61].
Though the biochemical studies above detail the differen-
tial expression of several key players in the glutathione meta-
bolism pathway, as well as the activity of GST, the actual
protein expression levels of GST have not yet been verified
at the biochemical level. Given that elevated levels of GST
were detected in four separate proteomic studies of DMD
(Supplementary Table 2), it would seem there is an opportu-
nity to examine this further and to determine whether it is
possible to alter the capacity of DMD cells to respond to
oxidative stress by manipulating GST expression and activity.
3.1.3. Increased membrane permeability in DMD
Increased membrane permeability is a hallmark of DMD and
though theories exist about what may cause this (reviewed by
Allen and Whitehead [62]), including contraction-induced tears
due to fragility of the already weakened membrane, oxidative
damage to membranes, or altered regulation of calcium ion
channels, the precise mechanisms remain elusive. An increased
level of serum albumin was detected across 10 separate
proteomic comparisons of DMD versus control tissues
(Supplementary Table 2) and likely reflects the increased mem-
brane permeability of the target tissue [56]. Indeed, damage-
induced disruption of muscle fiber membranes is commonly
associated with an influx of extracellular components, contain-
ing albumin, into the muscle [63] and has previously been
detected at the histological level in DMD muscles too [64,65].
Parvalbumin, on the other hand, was reduced across eight
separate proteomics studies and was one of only two proteins
showing a consistent decrease across the multiple proteomic
comparisons of DMD and control tissues (Supplementary
Table 2). In contrast, a separate proteomics-based biomarker
discovery project detected increased parvalbumin levels in
mdx mouse sera [66], possibly indicating that the reduction
of parvalbumin in DMD tissues may be a result of parvalbumin
leaking out into the extracellular space rather than an intra-
cellular-controlled mechanism. Reduced levels of parvalbumin
in DMD muscle have also been reported previously from
biochemical studies [67,68] and have been implicated in the
‘Ca2+ overload theory,’ proposed as a leading mechanism of
cellular degeneration in DMD (reviewed by Vallejo-
Illarramendi et al. [69]). Potential consequences of Ca2+ over-
load were also detected in multiple proteomic comparisons,
including an increased expression of the Ca2+-binding protein
troponin C (three comparisons) and increased expression of
the Ca2+-effector proteins, annexin 2 (eight comparisons), and
annexin 5 (six comparisons) (Supplementary Table 2). Does the
influx of albumin, another Ca2+-binding protein, also contri-
bute to Ca2+ overload mechanisms in DMD tissues?
3.1.4. Immune cells may contribute to the proteome of
DMD tissues
A prominent feature of DMD muscle is the presence of an
obvious immune response, though the functional conse-
quences of this are still a matter of debate [70]. Several
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types of immune cells have been shown to infiltrate mouse
and human DMD muscle, including macrophages, eosinophils,
natural killer T cells, CD4+, and CD8+ T cells [70]. Whilst pro-
teomics comparisons may have revealed insights into the
molecular response to this influx (e.g. increased levels of
leukocyte elastase inhibitor A (Supplementary Table 2)), it is
important to consider that each of these immune cell types
could potentially contribute a unique repertoire of proteins –
quite different from the muscle itself – and would thus skew
the proteomic profile of the sample. Western blot verification
of differential protein expression from total protein extracts
appears to have been common practice but few studies of this
nature have also provided histological analysis of the same
proteins, meaning that any changes in protein expression that
are related to tissue heterogeneity would likely be
unattributed.
3.1.5. Proteomic insights into the differential vulnerability
of muscles in DMD
Of note is that there are a large number of proteins (50+)
detected across the studies of the proteomic investigations
(summarized in Supplementary Table 1) that showed contra-
dictory patterns of expression in different comparisons (i.e.
increased in expression in one or more proteomic compari-
sons but decreased in others). Examples of such proteins are
GAPDH, various myosin chains, creatine kinase, glycogen
phosphorylase, myoglobin, and adenylate kinase (also identi-
fied in [71]). As alluded to previously, changes in the levels of
some of these proteins could be ‘false positives,’ arising from
variations in disease models, tissue heterogeneity, or tissue
sampling techniques. There is also the possibility, however,
that some of these differences may be useful for determining
which constitutive and/or adaptive molecular pathways con-
tribute to the differential vulnerability of different muscles
in DMD.
Two of the proteomics studies listed in Supplementary
Table 1 specifically aimed to shed light on the molecular path-
ways that determine how vulnerable a particular muscle type is
to an absence of dystrophin. A 2-dimensional difference in gel
electrophoresis-based quantitative proteomics comparison of
the mildly affected EOM from mdx and control mice revealed
differential expression of just seven proteins [55]. The authors
highlight how these results are a stark contrast to previous 2D-
gel-based comparisons of the severely affected diaphragm
muscle, where between 20 and 35 differentially expressed pro-
teins were detected [72,73]. This suggests that there is a mini-
mal perturbation of molecular pathways in the EOM muscle and
perhaps also implies that adaptive molecular pathways may not
extend far beyond a straightforward upregulation of the dys-
trophin homolog, utrophin [55].
A later study from the same group – in which the proteome
of the soleus (SOL), extensor digitorum longus (EDL), flexor
digitorum brevis (FDB), and interosseous (INT) muscles from
the mdx mouse was quantitatively compared with control
mice – also found differences between the number of differ-
entially expressed proteins across different muscle types [74]
(see Supplementary Table 1). The histological analysis revealed
a higher degree of hypertrophy and central nucleation (a
hallmark of muscle fiber regeneration) in the SOL and EDL
muscles compared to INT and FDB. This clearly does not
consistently correlate with the degree of differential protein
expression, however, since just 5 proteins were differentially
expressed in the INT but 19 were differentially expressed in
FDB (i.e. more than the number detected in the EDL muscle;
Supplementary Table 1). Notwithstanding the potential limita-
tions of 2D-gel-based quantitative proteomic comparisons,
these findings serve to highlight the importance of consider-
ing results from multiple tissue types before drawing general-
izable mechanistic conclusions about DMD.
3.1.6. Temporal proteomic studies of DMD
Several proteomic studies aimed to identify temporal changes
during disease progression in DMD mouse models. These
studies provide insights into the longer term secondary mole-
cular changes that occur during disease progression in mdx
mouse hindlimb muscle [71], cardiac muscle [75], tibialis ante-
rior [76], and diaphragm [77].
Some potentially interesting differences were detected in
aged hearts from mdx mice, including a reduction of lamin A/
C, vimentin, and annexin [75], that were both undetected in
the other aging studies and contrast with findings from var-
ious DMD versus control comparisons (Supplementary
Table 2). Though the authors were unable to verify the reduc-
tion of lamin A/C and vimentin by Western blot, reduced
levels of annexin were confirmed. In addition, while the
expression level of the developmentally regulated protein,
myosin light chain 2, was consistently increased in mdx
mouse hindlimb muscle at 1, 3, and 6 months of age com-
pared to age-matched controls [71], the levels in aged mdx
mouse hearts appear reduced compared to controls [75]. It is
clearly not possible to draw direct comparisons between the
various studies because of differences in the age of the tissue
being compared, but it would be interesting in the future to
determine whether the differential expression of such candi-
dates offers insights into mechanisms underlying the differen-
tial vulnerability of muscles in DMD.
3.2. Proteomic insights into other MDs
In recent years, several studies utilizing proteomics have
appeared in the literature surrounding these less prevalent
MDs with the aim of enhancing our understanding of the
molecular mechanisms underlying the downstream effects of
the causative mutations. The majority of these investigations
have employed human patient muscle tissue for comparative
characterization of protein expression versus controls, in an
attempt to distinguish groups of dysregulated proteins in
various MD subtypes. This has allowed the generation of lists
of differentially expressed proteins, providing indications of
the biological functions and pathways involved in the patho-
genesis of various MDs. However, there is a requirement for
larger numbers of well-executed studies to dissect cause/con-
sequence relationships and determine which alterations may
reflect conserved responses in the range of diseases.
The complexity of the genetic background of each disease
as well as the limited availability of human donors provides
challenges. Currently, there are only seven proteomic-based
studies focusing on the diseases discussed in Section 2 above,
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most of which have utilized 2D gels, followed by mass spectro-
metry (MS) analysis. Selected reports discussed here have
attempted to discern the commonalities and differences in
protein expression between genetic variants of particular
MDs as well as between diseases using these techniques (see
Supplementary Tables 3 and 4 for a summary).
3.2.1. DM1
There is only one readily available publication employing
proteomic techniques in an attempt to identify the molecular
cascades which are perturbed downstream of the causative
genetic insult in DM1. Hernández-Hernández and colleagues
[15] utilized a 2D-gel-based proteomic analysis on DM1 trans-
genic mice with 45 kb of human genomic DNA originally
cloned from a patient with DM1 [78,79]. Here, they identify
potential alterations in post-synapsin I (SYN1) translational
modifications and elements of RAB3a and its downstream
cascades. Various RAB alterations have been associated with
other neurodegenerative conditions including retinopthaies
[80], suggesting the possibility of conserved mechanistic cas-
cades across multiple apparently unrelated neurodegenerative
conditions. However, this study is limited by its choice of
controls, depth of coverage granted by the use of 2D gels
and lacks clarity in terms of identification of sample type used
for the experiments.
3.2.2. FSHD
At present, there are three proteomic studies attempting to
address distinct molecular alterations that may be specifically
associated with FSHD. An early study performed by Celegato
et al. [18] utilized 2 dimensional electrophoresis (2-DE), high
performance liquid chromatography–MS, and transcriptomic
methods to characterize deltoideus muscle protein expression
in groups of patients (aged 8–69 years) with varying D4Z4
repeat lengths. The group identified a common profile of
proteins associated with FSHD, independent of repeat size,
suggesting proteins associated with glycolysis, the tricar-
boxylic acid cycle, and protein synthesis (particularly, elonga-
tion factor Tu) are upregulated in patient versus control
samples; conversely, detoxification and degradation proteins
(SOD, PRDX2) and actin isoforms are downregulated in FSHD
patients. Proteins involved in muscle differentiation also
appeared to demonstrate differential expression between
FSHD patient groups and controls: these included COP9,
HSP27, alpha-crystallin B, phosphoglycerate mutase, creatine
kinase, and myosin heavy-chain proteins. Upon further analy-
sis, the study identified a conserved upstream regulator –
MyoD, levels of which were shown to be consistently reduced
in patients. The authors hypothesized that defects in MyoD
signaling promoted the failure of regeneration of fast glycoly-
tic muscle fibers after episodes of mechanical stress, leading to
a progressive increase in slow oxidative fibers, promoting
weakness and dystrophy in FSHD patient muscle.
In a similar study by Laoudj-Chenivesse et al. [21], 2-DE
proteomics coupled with MS also identified alterations in the
detoxification and oxidative stress machinery in FSHD patient
muscle biopsies. The specimens were obtained from the del-
toideus and quadriceps muscles and included a range of
individuals (aged 17–66 years), all demonstrating various
D4Z4 repeat lengths. Although there appear to be overlaps
in the pathways detected between the Laoudj-Chenivesse
et al. [21] study and the work performed by Celegato et al.
[18], the directionality of the protein expression alterations
contrasts. For instance, Celegato et al. [18] report the down-
regulation of proteins associated with detoxification pro-
cesses, whereas Laoudj-Chenivesse et al. [21] demonstrate a
significant upregulation of these cascades (proteins include
SOD1 and GST). Due to the reported upregulation of oxidative
stress markers, the Laoudj-Chenivesse et al. [21] study focused
on the potential impact of mitochondrial dysfunction on mus-
cle fiber integrity that was hypothesized to be regulated by
increased ANT1 expression – a gene neighboring the D4Z4
repeat locus.
The final study concerning FSHD has provided another per-
spective on the molecular pathogenesis of the disease. Tassin
et al. [20] utilized patient-derived myoblasts (n = 2) and gel-free
shotgun proteomics (2DLC–MS/MS) to characterize atrophic
and disorganized FSHD myotubes versus control cells. In total,
336 proteins were quantified from the quadriceps-derived myo-
blasts with the study illustrating that myosin heavy and light
chain (MYH8, MYH3, MYH7; MYL1, MYL6B) and caveolar pro-
teins appeared dysregulated in primary FSHD cells. The authors
highlighted caveolin-3 (CAV3) and its associated networks as
potentially perturbed in FSHD promoting the reduction of myo-
genic differentiation in skeletal muscle. CAV3 mutations have
previously been documented in other neuromuscular diseases,
including LGMD1 and LGMD2B, which may suggest that caveo-
lin dysregulation is a consequence of myotube degeneration as
opposed to an upstream regulator of FSHD.
3.2.3. Molecular overlaps across multiple dystrophies
There is a requirement for further comparative studies in order to
elucidate how these membrane micro-domains may play a role
in pathogenesis. One such study by De La Torre et al. [81]
similarly documented an impairment in myotube differentiation
in LGMD2B patient muscle biopsies. This comparative investiga-
tion focused on differentially expressed proteins between
LGMD2A, LGMD2B, FSHD, and control triceps and quadriceps
muscle using 2-DE and MALDI–TOF MS. The authors provided
details on 17 conserved proteins that appear altered in all the
neuromuscular diseases characterized versus the control sam-
ples. These proteins displayed involvement in energy metabo-
lism, themyofibril, andmuscle development and repair, agreeing
with the previously discussed manuscripts studying FSHD. Much
like the Celegato et al. investigation [18], the group shows altera-
tions in themuscle fiber distribution with a significant increase in
slow-twitch fibers. These remodeling events appear to be occur-
ring in numerous neuromuscular diseases and track with disease
progression. The authors also elaborated to include proteins that
demonstrated alterations specifically in LGMD2B patients. These
14 candidates exhibited similar functional categories to those 17
that were conserved through the neuromuscular diseases exam-
ined. Although in the De La Torre et al. study [81] these proteins
appeared to demonstrate unique alterations in LGMD2B
patients, upon further inspection of the literature, there are
indications that several of these candidates have been discussed
in a range of neuromuscular diseases including collagen VI
6 H. R. FULLER ET AL.
D
ow
nl
oa
de
d 
by
 [T
he
 U
niv
ers
ity
 of
 E
din
bu
rg
h]
 at
 04
:10
 08
 Ju
ly 
20
16
 
myopathies (De Palma et al. [39]), FSHD (Celegato et al. [18]), and
Duchenne MD (see Supplementary Table 4).
Considerable overlaps exist between investigations examin-
ing FSHD and LGMD subtypes, which may be due to the
upstream regulators of disease or the conserved downstream
processes of muscle degeneration. Magagnotti et al. [82] also
noted similar pathways may be disrupted in EDMD with
patients harboring mutations in the LMNA gene, namely
LGMD1B. 2-DE proteomics, MALDI–TOF MS, and in silico ana-
lyses of patient fibroblasts suggested that proteins regulating
cytoskeletal/structural organization were less abundant in indi-
viduals with a diagnosed laminopathy. Conversely, and in keep-
ing with the Laoudj-Chenivesse et al. FSHD study [21], oxidative
stress markers appeared enriched in patient cells versus con-
trols. Despite Magagnotti et al. [82] utilizing groups of patients
with general myopathies as an internal control to assess specific
protein alterations in laminopathies, it is clear from examination
of multiple published data sets that several of these candidates
have been reported to be differentially expressed in other
neuromuscular diseases (see Supplementary Table 4 [18,20–
21,39,49,54–56,72–74,81–83,92–94,99]).
Suggestions of skeletal muscle remodeling in MDs are fre-
quently referenced in the literature due to the dynamic altera-
tions in proteins involved in myofibrillar architecture and
cytoskeletal integrity (Celegato et al. [18], Tassin et al. [20], De
La Torre et al. [81], Magagnotti et al. [82] – see Supplementary
Tables 2 and 4). De Palma et al. [83] also proposed that in
LGMD2B patients, there was a redistribution of muscle fiber
type as proteins involved in oxidative phosphorylation were
increased and those associated with anaerobic metabolism
decreased versus control samples. In accordance with the altera-
tions in expression of bioenergetic candidates, myosin light-
chain isoforms were also differentially expressed in the
LGMD2B patients’ quadriceps muscle, suggesting functional
impairments in contractile velocity and force may be due to
increased numbers of slow-twitch fibers.
A further study conducted by the same authors (De Palma et al.
[39]) focused on the collagen VI myopathies: UCMD and BM (see
Section 2.6). Human quadriceps muscle biopsies from BM (n = 8),
UCMD (n = 4), and control (n = 2) patients revealed bioenergetics
pathways were altered in both BM and UCMD individuals versus
healthy samples. The downregulation of the hexosamine biosyn-
thetic pathway (HBP) was highlighted as a key driver of BM and
UCMD progression due to associations with protein homeostasis
in the endoplasmic reticulum and unfolded protein response
systems. Although this reduction in the HBP and glycosylation
appeared conserved between the collagen VI MDs, the down-
streambiochemical alterations in UCMD and BMdisplayed unique
properties, likely reflecting the differences in disease severity. In
BM patient samples, the authors suggest that the muscle protein
quality control system is sustained by metabolic adaptation. This
allows the cells’ energy requirements to be met and the cata-
strophic consequences of the ER protein misfolding response to
diminish. In contrast, UCMD patients demonstrate disruption in
this pathway and the compensatory-layered mechanism, likely
leading to lipotoxicity and cellular apoptosis. Interestingly, other
MDs such as spinal muscular atrophy (SMA) demonstrate pertur-
bations in proteostasis with ubiquitin homeostasis defects influ-
encing neuromuscular pathology [84] (see Section 2.1).
3.2.4. In silico analysis suggests proteomic studies are
highlighting downstream consequences of degenerative
cascades
Although the appearance of common themes in the MD field
may permit enhanced understanding of the molecular pathol-
ogy of the various diseases, it may also be a great hindrance.
The proteomic studies discussed examined groups of hetero-
geneous conditions caused by numerous discrete genetic
mutations that all encode for different proteins, pathways,
and processes (see Section 2). Thus, the emergence of these
conserved changes in cytoskeletal and bioenergetic families
throughout various neuromuscular disorders suggests that
these alterations are likely a downstream consequence of
causal upstream perturbations. Many alterations are likely an
adaptive response to ongoing myofibril degeneration – a
process occurring in all MDs discussed. In fact, with in silico
analysis of the proteins identified in Supplementary Table 4,
there are clear indications that a substantial number of these
candidates may be involved in downstream degenerative cas-
cades occurring in a wide range of tissues – not merely
myofibrils (Figure 1(a)). Alterations in expression of upward
of 15 of these proteins have been associated with Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease, and motor
neuron disease in published manuscripts (Figure 1(b)), illus-
trating likely late-stage consequences of cellular dysregulation.
Thus, it is probable that these candidates do not represent
viable therapeutic targets or biomarkers for MDs. Despite this,
vimentin is consistently identified as upregulated throughout
the different MD studies. Interestingly, vimentin also appears
to lie upstream of the majority of the candidates identified by
the investigations reviewed here (Figure 1(c)). These observa-
tions may warrant further analyses into what lies further
upstream of vimentin and how this may be potentially pro-
moting dysregulation selectively within the myofibrillar archi-
tecture. However, in order to successfully elucidate the
upstream regulators of various MDs, there are several consid-
erations that require attention before experimentation.
Fortunately, the field is now in the position to successfully
draw on lessons learned from other fields (such as SMA),
where considered applications of proteomic techniques have
yielded tangible gains (Figure 2).
4. Future directions in dystrophy research through
proteomic investigations
The data sets reviewed in Section 3 provide novel and valuable
insights into the molecular pathways that may be disrupted in
MDs. The search for conserved and uniquemolecular alterations in
MD variants has begun to shed light on the downstreampathways
affected by these discrete mutations. Despite this, the current
studies demonstrate some shortcomings in proteomic experimen-
tal design and data analysis that should be addressed.
4.1. Tissue selection and characterization
The investigations discussed in this review appear to focus on
static stages of disease in a variety of animal model or pooled
patient samples. This is a fundamental flaw whilst attempting to
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elucidate biomarkers of disease progression because this
approach does not account for the numerous variables that may
have influenced the data acquired. Primarily, there appears to be
an oversimplification of proteomic investigations, leading to the
loss of potentially relevant information thatmay indicate howMDs
are regulated. Commonly, the studies report two-way compari-
sons of pooled samples: disease versus control patients; however,
the patient cohorts vary significantly. Within the MD pooled
patient (and animal model) samples, authors include tissues
from a variety of muscles, ages, clinical severities, and genetic
mutations – promoting substantial heterogeneity and preventing
the possibility of also running a variable-matched control sample.
It is now well established that different tissues and even various
anatomical regions of the same tissue sample (e.g. proximal versus
distal) do not display uniformity in protein expression [85]. Thus,
pooling or comparing numerous biopsies from awide selection of
skeletal muscles and cellular populations will only hamper the
identification of proteins regulating pathogenesis.
In contrast to the majority of studies conducted on other
MDs, the vast majority of proteomic investigations into DMD
have utilized tissue from the mdx mouse and whilst two
proteomics studies of DMD patients have been conducted,
one utilized serum [47] and the other analyzed urine [48].
These sources can certainly be useful for identifying easily
accessible biomarkers of disease as demonstrated by
Coenen-Stass and colleagues’ [86] innovative identification of
peripherally accessible biomarkers which demonstrate
response to therapeutic attempts in mdx mice. However,
such peripherally accessible samples do not necessarily offer
easily translatable mechanistic insights into disease pathology.
For example, while one protein may appear elevated in the
serum of DMD patients, its expression in the primary tissue
(i.e. muscle) could be entirely the opposite. In order to deter-
mine that alterations in protein expression are due to the
presence of disease, the same ages, sexes, and clinical seve-
rities of patients, as well as muscle, and, ideally, the same
portion of muscle, must be utilized in the pooled MD and
control samples. Furthermore, in order to understand disease
mechanisms, it is imperative that protein expression in indivi-
duals without the condition is characterized so analogous
alterations can be eliminated as pathogenic.
4.1.1. Characterization of protein expression profiles
throughout disease progression
The degenerative process displays complex and dynamic spa-
tiotemporal molecular profiles, which demonstrate variability
Figure 1. Pathways analysis of conserved overlaps in Muscular Dystrophies. (a) Top canonical pathways bar chart highlighting the main disrupted cascades in
multiple MD subtypes (data from supplementary table 4). By combining data from several proteomic studies we are able to identify pathways such as multiple Rho-
related cascades or ‘Clathrin-mediated endocytosis signalling’ which were not specifically reported to be disrupted in these studies. (b) Network highlighting how
candidates identified in multiple MD proteomic studies interact with other neuronal/neuromuscular diseases. Alzheimer’s, Parkinson’s, Huntington’s and X-linked
hereditary diseases demonstrate similar protein expression alterations suggesting these proteins may be involved in downstream degenerative cascades. (c) Top
identified network in IPA generated from MD candidates. Vimentin (VIM) appears as a central hub of the network impacting to multiple downstream proteins. Lines
in blue indicate VIM interactions with other proteins with a conserved change in multiple datasets. (b–c) All proteins listed in supplementary table 4 were included
in the IPA analysis. Candidates with reported quantitative values in >2 studies and demonstrating consistent alterations (up-/or down-regulation) across >50% of
these studies were considered for the IPA statistical testing. These proteins were assigned an arbitrary fold-change value of +2 or −2 respectively, for the generation
of IPA data. Red = up-regulation; green = down-regulation; grey = proteins not considered for statistical analysis. Dotted lines indicate direct interactions; dashed lines,
indirect interactions. (Full color available online).
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throughout disease progression dependent upon the
upstream genetic mutation. Fluctuations in protein expression
throughout the disease course indicate tissue-specific cas-
cades, with differing biochemical alterations often occurring
in neighboring populations of cells [87]. These varying protein
expression profiles often reflect the vulnerability status of
particular cellular clusters that display an enhanced response
to insult. In order to determine how alterations in protein
expression may modulate cellular and tissue vulnerability, it
is important to track candidate alterations through the time
course of MDs – from early presymptomatic time points to
end-stage disease. There is abundant evidence to suggest that
alterations in causative upstream molecular cascades begin
long before the onset of detectable pathology [84]. From our
own studies, we have observed significant up/downregulation
of numerous proteins during the early stages of disease but at
later time points, protein expression is quite the contrary [87].
Therefore, focusing on the early stages of disease may provide
an enhanced understanding of the molecular mechanisms
governing muscle degeneration and offer a viable data source
for the identification of novel drug targets. Additionally, a
comparison of multiple disease variants (i.e. Duchenne vs.
Becker–Kiener dystrophinopathy) with differing severity may
also offer more tenable insights into potential upstream mod-
erating and/or regulating molecular cascades.
4.1.2. Proteomic techniques
The availability of modern proteomic techniques is beginning
to direct the field away from 2D gels. Tools such as label-free
proteomics as well as labeled approaches including isobaric
tags for relative and/or absolute quantitation (iTRAQ) or tan-
dem mass tagging enable a more comprehensive character-
ization of the molecular alterations occurring throughout
disease progression. Label-free techniques enable compara-
tive analyses of multiple samples with low concentrations of
protein extracts [87,88], which may be beneficial when work-
ing with precious resources such as human patient samples.
These techniques enable analysis with a little as 3–5 µg of
material for injection into an orbitrap. There are of course
limitations with the existing tools such as limited dynamic
range, compression of ratios calculated for tagged samples,
and even something as basic as coverage of the proteome
when compared to more established transcriptomics. Whilst
transcriptomics may be ahead of proteomics in coverage and
usability, it is protein and not RNA which are the ultimate
effector molecules and the two do not necessarily correlate
well [89]. Therefore, continued developments for the field of
proteomics in software (such as Progenesis) that allow the
processing and analysis of complex timecourse profiles and/
or comparisons, facilitate improved methodologies in the MD
field.
4.1.3. Data analysis
Filtering and refining of proteomic data is absolutely essential.
There remains a requirement for laboratories to follow stan-
dardized criteria in order to provide more reliable and com-
parable analyses in publications. For example, posttrans
lational modifications (PTM) and distinct isoforms should be
reported (if known), as they may be a source of contradictions
Figure 2. Experimental design and workflow. Description of the experimental
planning and process ranging from ‘Tissue Sampling’ to ‘Validation’ of the data
produced by proteomic techniques. The combination of the selection of specific
model/muscle type/time-point of disease progression, high-throughput proteo-
mic technique, strict data filtering and unbiased bioinformatics analyses fol-
lowed by validation are basic steps to follow. We encourage future proteomic
studies to consider this workflow in order to produce good quality data to aid in
elucidating the mechanisms regulating muscle degeneration.
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in the data shown. If the technique/software/database for the
identification of protein used is not able to distinguish
between protein isoform/PTM, strict filtering should be
applied to avoid low-quality identifications. The re-reporting
of published data sets without reanalysis has the potential to
propagate erroneous conclusions throughout published litera-
ture within the field. Investigators should also utilize available
software for in silico analyses. These tools enable unbiased
comprehension of the pathways and processes that may be
altered within the samples analyzed. It has become increas-
ingly clear that discrepancies exist in the data reported by
investigators and this affects the outputs from independent
pathway analyses (see Supplementary Tables 2 and 4 and
Figure 1).
5. Five-year perspective on advancements in MD
research
The relatively recent advances in proteomic tools and techni-
ques (as discussed in Section 4), coupled with the broad range
of disparate mutations leading to multiple forms of dystrophy
with varying prevalence, have (to date) severely impeded a
coherent approach to the molecular characterization of the
downstream molecular cascades regulating the vulnerability
of distinct muscle populations and the progression of indivi-
dual disease variants. We have outlined various experimental
obstacles in Section 4, which require attention before con-
ducting proteomic experiments (Figure 2).
There is clearly scope for future work in this area, using
modern approaches such as iTRAQ or label-free MS, to quan-
titatively compare the proteome of MD muscles that show
differential vulnerability. Indeed, recent publications examin-
ing other neurodegenerative conditions such as the childhood
motor neurone disease SMA have taken a concerted proteo-
mic molecular genetic approach to identify regulators path-
ways and therapeutic targets [84]. Here, the authors applied
iTRAQ proteomics to vulnerable neuronal populations in a
SMA murine model to identify differentially expressed pro-
teins. Selected candidates were examined for their ability to
regulate neuronal stability in multiple small animal model
systems including Drosophila and zebrafish before scaling
back up to murine systems providing a complete rescue of
the neuromuscular system. As a result, the authors have pub-
lished the most effective non-survival motor neuron replace-
ment therapy to date. The samples and models exist within
the dystrophy field to allow the replication of such proven
target-rich workflows to be implemented to inform novel
(non-replacement-based) therapeutic interventions for the
dystrophies.
6. Expert commentary
Current proteomic studies regarding inherited MDs are unra-
veling common/specific disrupted pathways in terms of the
molecular constituents altered, but these candidates are not
necessarily altered in a consistent manner due to the nature of
the investigations/experimental design employed. Though
they provide a window for a better understanding of the
process of degeneration, some issues should be addressed in
future work. The development of novel proteomics, such as
label-free techniques, facilitates a more complex experimental
design where factors such as tissue-specific vulnerability and
disease stages may be taken into account. This will allow
researchers to distinguish between early and late responses
of the specific mutations causing MDs and a more accurate
mapping of the dynamic processes taking place in the muscle.
Moreover, the production of animal and cellular models that
faithfully recapitulate the disease phenotype seen in patients
will also help for a more comprehensive characterization of
the molecular changes taking place throughout disease pro-
gression than can later be correlated to human disease. As
there are currently no effective therapeutics for the dystro-
phies, the field is reminiscent of where the SMA field was
10 years ago, i.e. gene replacement therapy is on the extreme
horizon, but the tools and techniques are available to make
some tangible headway into our understanding of the disease
processes underpinning the condition leading to the identifi-
cation of novel potential non-gene replacement therapeutics
along the way [84,87].
Key issues
● Proteomics is a powerful tool for the identification of bio-
markers and therapeutic targets.
● Investigators must endeavour to utilise strict and standar-
dised methodologies for comparison of control and disease
tissues.
● If identified candidates are enzymes or have a role in meta-
bolic processes, ex vivo biochemical or in vivo reporter
assays (in model organisms i.e. Drosophila) should be per-
formed to determine if detection of altered abundance
correlates with altered activity/function.
● Studies should utilise western blotting and immunohisto-
chemical analysis, as well as multiple model organisms for
validation of candidate relevance to human physiological
alterations and to assess their ability to moderate disease
processes in vivo.
● Such candidates should be assessed for their ability to
moderate disease processes in vivo and in multiple organ-
sims (i.e. Drosphila/Zebrafish/Rodents) in order to confirm
relevance in a species/model independent manner.
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